there seems to be some heavy resistance around these level with a lot of potential upside.

Final Results.

Unaudited Preliminary Results Announcement for the year ended 31 December 2011

GSK delivers continued underlying sales growth*, R&D progress and improving financial returns to shareholders

2011 underlying sales +4% (reported -3%); EPS before major restructuring* 114.1p; total dividends of 75p.

Glaxo invests £500m in UK and builds new factory

Drugmaker GlaxoSmithKline has said it will invest £500m in manufacturing in the UK, including building a new factory in Ulverston, Cumbria.

The investments could create up to 1,000 new jobs, Glaxo said. The biopharmaceutical facility will be its first new UK factory for 40 years.

Glaxo said it was "one of the largest commitments to the UK life-sciences sector in recent years".

1st Quarter Results.

GSK reports sales growth (+2% CER), further R&D delivery, operational leverage and continued
returns to shareholders
- Core* EPS 27.3p (+7%)
* Dividend up 6% to 17p; total 2012 share buyback now
expected to be GBP2-GBP2.5 billion including non-core
OTC disposal proceeds

GSK signs worldwide acquisition for Toctino

Stiefel, a GSK company, today announced that it has entered into a worldwide agreement to acquire Toctino (alitretinoin) from Basilea Pharmaceutica Ltd. (Basilea). Toctino is a once-daily oral retinoid and the only prescription medicine specifically approved for the treatment of severe chronic hand eczema unresponsive to potent topical steroids in adults. It is commercially available in 14 countries, approved in an additional 15 countries, and is in a Phase 3 trial in the US. In 2011, worldwide sales of Toctino were £22m.

1st Quarter Results

Summary

■ Group sales -2% reflecting continued contribution from key growth drivers offset by expected demanding prior year comparisons:

- Sales +2% excluding divestments (primarily Vesicare and non-core OTC brands)

- Pharmaceuticals and Vaccines sales -2%: US -6% (+4% excl. Vesicare with strong respiratory and oncology performances), Europe -3%, EMAP +8%, Japan -8% (+11% excl. Cervarix)

- Consumer Healthcare +1% (+6% excluding divestments)


■ Continued R&D pipeline progress:

- Positive FDA Advisory Committee recommendation for use of Breo Ellipta in treatment of COPD; FDA Action date 12 May

- MEK monotherapy, MEK/BRAF combination use and albiglutide filed in Europe; dolutegravir granted Priority Review in US; Anoro Ellipta filed in Japan


■ Continued delivery of financial efficiencies, strong cash generation and returns to shareholders:

- Adjusted net cash inflow from operating activities of £1.4 billion (Q1 2012: £1.1 billion)

- Initial phases of new major change programme, including European restructuring, progressing well

- Q1 core tax rate 22.4% reflecting benefit of US R&D tax credit; continue to expect full year core tax rate of around 24%

- Q1 dividend: 18p, +6%; continuing to target share repurchases for the year at £1-2 billion


■ Further measures to drive strategic focus and improve growth profile:

- Strategic review of Lucozade and Ribena completed; decision to pursue divestment subject to appropriate value realisation

- Pharmaceutical tail brands (with 2012 sales of around £3 billion from over 50 brands) to be formed into a Global Established Products portfolio; co-ordinated and reported separately from January 2014


■ 2013 expectations for sales growth (~1%) and core EPS growth (3-4%) unchanged (both at CER)

GSK puts Lucozade and Ribena drink brands up for sale

LONDON | Wed Apr 24, 2013 1:45pm BST
(Reuters) - GlaxoSmithKline is to sell soft drink brands Lucozade and Ribena in a move analysts believe will raise over 1 billion pounds and focus its consumer health business on global products.

The plan was announced on Wednesday alongside first-quarter results that saw sales at Britain's biggest drugmaker drop a slightly smaller-than-expected 3 percent from a year ago.

China security ministry says GSK executives confess to crimes

BEIJING | Thu Jul 11, 2013 7:14am BST
(Reuters) - Executives of British drug maker GlaxoSmithKline Plc in China have confessed to charges of bribery and tax law violations after initial questioning by Chinese police, China's security ministry said on Thursday.

The company is suspected of offering bribes to government officials, medical associations, hospitals and doctors to boost sales and prices, the ministry said in a statement on its website.

GSK is also suspected of using fake receipts in unspecified tax law violations, the ministry said.

MAGE A-3 Phase III DERMA Study Results

GlaxoSmithKline plc (LSE:GSK) today announced that an independent analysis of the DERMAi study, a Phase III randomised, blinded, placebo-controlled trial of the MAGE-A3 cancer immunotherapeuticii showed that the study did not meet its first co-primary endpoint as it did not significantly extend disease-free survival (DFSiii) when compared to placebo in the MAGE-A3 positive population.

3rd Quarter Results

April 23 - After the hallabaloo:


JP Morgan Cazenove: Neutral - Reiteration

Credit Suisse: Underperform - TP held at 1600p - Reiteration

UBS: Neutral - TP held at 1500p - Reiteration

Deutsche: Hold - TP raised from 1620p to 1750p - Reiteration

Societe Generale: Buy - TP held at 2088p - Reiteration

June 16: Societe Generale: Buy - TP: 2100p.

Ages since I saw such an upbeat TP.

News not RNS

More about the GSK sex tape

July 2: Deutsche: Hold - TP: 1630p.

Latest episode in the GSK saga.

July 7: Credit Suisse: Underperform; TP: 1600p
.

July 14:
Jefferies reiterates: Hold - TP down from 1610 to 1460p.

Credit Suissse reiterates: Underperform - TP retained: 1600p.

July 15: UBS: reiterates Neutral - TP: 1500p.

GSK falls after results.

GlaxoSmithKline good value at 1428p

BY ROBERT SUTHERLAND SMITH | TUESDAY 29 JULY 2014

The fall in the GlaxoSmithKline (GSK) share price to1428p is a story in its self. Not only is it back to where it approximately was in 2013 but it now stands on what I perceive to be a three year support level. (Have a look for yourselves.) If so, will the share price hold there and is it a reason to buy the shares as cheap at 1428p on an historic dividend yield of 5.4% and on the basis that “there will always be a Glaxo”; an approach that has generally speaking been a good point to buy the shares when the news looks bleakest?

The results for the first half of the current year were dire. With turnover down 12% should be attribute that to the simple strength of Sterling. Evidently not; because when you take that into account revenue still fell 3% in constant exchange value terms. Was the full impact of generic competition for its main drugs; or the fact that having been caught up in accusations of bribing doctors in China to prescribe its drugs a head of those of competitors? The company has reportedly now made drastic reforms to its selling and marketing policies my breaking such a link to sales personnel pay. It is impossible to judge from outside the company.

The annual dividend last year cost £3.7 billion. It is good to see that balance sheet end year cash has been rising for £3.9 billion the previous year to £5.2 billion last year. So in the meantime, there appears to be sufficient cash in the balance sheet to finance dividends, though cash generation has to be an ever ongoing process. Glancing at the market consensus estimates, I see that there is still a clear expectation of a progressive dividend policy with consensus of analysts expecting dividends to increase 4% this year and about 4.4% next year putting, Glaxo shares on prospective annual dividend yields of an estimated 5.7% for this year and 6.0% for next year. It is to be noted that the Q2 dividend payment of 19p for Q2 was reportedly 6% up on the amount paid last year.

The market in its consensus forecasts is also estimating a 13% fall in earnings this year but an increase of 8% next year. When reading the report you will see that the management speaks confidently about its drug development programme referring to 40 near approval entities in late stage development. It may not have a cure for the Ebola virus but it will be bring much needed new drusg to market. It adds that 30% of its R&D assets have, in the view of the company, the potential to “first class” in the companies chosen areas of therapeutic medicines. Furthermore, the joint venture with Novartis in vaccines which the two companies have put intellectual property and research and development assets, has the potential, says GSK, to grow around half of the Group’s future revenue. In the final analysis, the company has now openly discussed a possible future sale of its consumer, over the counter health care business, if necessary, with the caveat that retaining it provides scales of economy for the business in the important emerging markets. It does not sound as though they are rushing to do that.

It strikes me that the perceived three year support line on the share price chart sits nicely with a high yield together suggesting that the shares look good value in dividend yield terms after a period of bad news and particularly poor results.

- See more at: http://www.shareprophets.advfn.com/views/6849/glaxosmithkline-good-value-at-1428p#sthash.ACUhuWnY.dpuf